Table 1 Patient’s characteristics and clinical course
From: GNRHR-related central hypogonadism with spontaneous recovery – case report
Baseline | After 1 year of testosterone th | After 2 years of testosterone th | 2 years after cessation of testosterone th | |
|---|---|---|---|---|
Age (years) | 16 | 17 | 18 | 20 |
Bone age (years) | 14.7 | / | / | / |
Bone age SDS | -1.48 | / | / | / |
Height (cm) | 178.8 | 182 | 185 | 188.8 |
Height SDS | 0.62 | 0.72 | 1.11 | 1.64 |
Weight (kg) | 88.2 | 84.65 | 90.4 | 99 |
Weight SDS | 2.11 | 1.63 | 1.92 | 2.39 |
BMI (kg/m2) | 27.59 | 25.56 | 26.4 | 27.79 |
BMI SDS | 2.13 | 1.48 | 1.55 | 1.73 |
Testicular volume (mL) | 4 | 4 | 4 | 20 |
Tanner stage | 2–3 | 3 | 4 | 4–5 |
Basal LH (IU/L) LoD 1.8 IU/L ≤ 7% CV | 0.9 | / | / | 3.8 |
Basal FSH (IU/L) LoD 0.6 IU/L ≤ 7% CV | 2.2 | / | / | 10.4 |
Peak stimulated LH (IU/L) | 6.58 | / | / | 18.2 |
Peak stimulated FSH (IU/L) | 3.58 | / | / | 15.6 |
Testosterone (nmol/L) LoD 0.17 nmol/L ≤ 10% CV | 0.8 | 11.8 | 18.3 | 23.6 |
Inhibin B (ng/L) LoD 2.91 ng/L ≤ 6.6% CV | 85.8 | / | 126.6 | 99.3 |